Osilodrostat: First Approval.

Article Details

Citation

Copy to clipboard

Duggan S

Osilodrostat: First Approval.

Drugs. 2020 Mar 5. pii: 10.1007/s40265-020-01277-0. doi: 10.1007/s40265-020-01277-0.

PubMed ID

32141023 [ View in PubMed

]

Abstract

Osilodrostat (Isturisa((R))) is an orally available small molecule 11beta-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.

DrugBank Data that Cites this Article

Drugs

Osilodrostat

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Osilodrostat	Cytochrome P450 1A2	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Cytochrome P450 2D6	Protein	Humans	Unknown	Substrate Inhibitor	Details
Osilodrostat	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate Inhibitor	Details
Osilodrostat	Cytochrome P450 3A5	Protein	Humans	Unknown	Inhibitor	Details

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Osilodrostat	Multidrug and toxin extrusion protein 1	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Solute carrier family 22 member 1	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Solute carrier family 22 member 2	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Solute carrier family 22 member 6	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Solute carrier family 22 member 8	Protein	Humans	Unknown	Inhibitor	Details
Osilodrostat	Solute carrier organic anion transporter family member 1B1	Protein	Humans	Unknown	Inhibitor	Details